MMTX.SW MindMaze Therapeutics (SIX) down 10.21% to CHF0.77 on 25 Feb 2026: oversold, watch support
MMTX.SW stock opened at CHF0.90 and traded down to CHF0.72 intraday, closing the session around CHF0.77, a -10.21% move on 25 Feb 2026. This sharp drop amplified an ongoing YTD decline of -50.65%, and volume rose to 571,343 shares versus an average of 375,875. The price sits well below the 50‑day and 200‑day averages of CHF1.45, signalling market stress. We examine drivers, technicals, sector context and what Meyka AI’s model and grade say about short‑term risk and potential recovery.
MMTX.SW stock: Intraday price action and volume
MMTX.SW stock touched a day low CHF0.72 and a day high CHF0.90 on heavy trading. The stock moved from the previous close of CHF0.85 to CHF0.77, down -10.21%. Volume reached 571,343, a relative volume of 1.53, indicating above‑average selling pressure.
MMTX.SW stock: What drove today’s sell‑off
Traders cited thin liquidity and profit taking after the post‑IPO re‑rating in late 2025. There was no scheduled earnings release; EPS and PE remain N/A, which keeps valuation opaque. The company web update and sector chatter pointed to slower adoption timing for its digital therapeutics platform, pressuring sentiment. The lack of clear near‑term revenue milestones amplified selling.
MMTX.SW stock: Technicals show oversold conditions
Technical indicators are deeply oversold and trending lower. RSI sits at 15.53, MACD is -0.07 with a signal at -0.04, and ADX reads 36.08 suggesting a strong trend. Momentum measures show CCI -249.36 and Stochastic %K 5.70, indicating potential for a short‑term bounce but continued downside risk. Bollinger middle band is CHF1.05, offering the nearest resistance.
MMTX.SW stock: Fundamentals and sector comparison
MindMaze Therapeutics Holding S.A. trades on SIX with a market cap of CHF116.74M. The firm has no reported EPS and listed in December 2025, which complicates forward valuation. Healthcare peers trade on average PE 35.02 and stronger current ratios. Compared to the healthcare sector performance, MMTX.SW’s YTD -50.65% underperforms the sector YTD +1.48%, highlighting stock‑specific weakness.
MMTX.SW stock: Meyka AI grade and model forecast
Meyka AI rates MMTX.SW with a score out of 100: 62.74 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of CHF0.35, implying -54.25% versus the current CHF0.77. Forecasts are model‑based projections and not guarantees.
MMTX.SW stock: Risks, support and realistic price targets
Immediate support sits at today’s low of CHF0.72 and the year low CHF0.72, while intraday resistance is near the Bollinger middle band CHF1.05. Realistic near‑term scenarios: a bearish target at CHF0.50 and a recovery target at CHF1.20 if adoption accelerates and liquidity improves. Watch trading volume and clinical or commercial updates closely.
Final Thoughts
MMTX.SW stock is an intraday top loser on 25 Feb 2026, sliding to CHF0.77 on heavy volume and deep technical oversold signals. The healthcare sector remains firmer, which highlights company‑specific concerns for MindMaze Therapeutics Holding S.A. Meyka AI rates the stock 62.74 (Grade B, HOLD) and flags mixed signals from sector peers and limited fundamental history. Meyka AI’s forecast model projects monthly CHF0.35, an implied -54.25% versus the current price CHF0.77; this is a model projection, not a guarantee. For traders, key actions are watchlisted: monitor volume, news from the company website, and whether price can reclaim CHF1.05 as resistance. Long‑term investors should await clearer earnings and adoption milestones before increasing exposure. For our full live quote and trend tracker, see the Meyka stock page for MMTX.SW and the company site for official releases.
FAQs
What caused the intraday drop in MMTX.SW stock today?
The intraday drop to CHF0.77 followed higher volume, absence of EPS data, and profit taking after the IPO re‑rating; no new earnings were released.
How does Meyka AI assess MMTX.SW stock right now?
Meyka AI rates MMTX.SW 62.74 (B, HOLD) and projects a monthly model price of CHF0.35, noting this is a model projection and not a guarantee. Check updates before action.
What are the technical warning signs for MMTX.SW stock?
Key warnings are RSI 15.53, CCI -249.36, ADX 36.08, and price below the CHF1.45 50‑day average, indicating strong downside momentum and oversold conditions.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.